PRINCETON, NJ--(Marketwire - November 10, 2008) - Patients with type 2 diabetes face many challenges, including blood sugar monitoring, maintaining a healthy diet and transitioning to new therapies. Novo Nordisk (NYSE: NVO), the world's largest maker of insulin, is committed to helping new patients make the move to insulin. As part of that commitment, the company is announcing its Levemir® Satisfaction Guarantee for U.S. patients taking Levemir® (insulin detemir [rDNA origin] injection) to treat type 2 diabetes.
